SBFM - Sunshine Biopharma, Inc. P/S Multiple
The lack of mass sales due to the laboratory status of developments restricts the reduction of unit costs for Sunshine Biopharma (SBFM). However, ownership of patents for antiviral and oncology drugs will ensure control over therapy costs in the future. High competition in the generics segment necessitates the protection of R&D. The company's normalized P/S reflects the dynamics of capitalization to revenue, where the 0.10 mark characterizes this parameter.
Analytical breakdowns for Sunshine Biopharma (SBFM)
- price and consensus price forecast:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Sunshine Biopharma|SBFM - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient sunshinebiopharma.com|SBFM - Company Debts|Debt to Book Value Ratio Sunshine Biopharma|SBFM - Company Long-Term Debts|Short-Term Debt Sunshine Biopharma|Intermediate Coverage Ratio sunshinebiopharma.com
- net income and valuation multiples indicators:
SBFM - Net Profit|Expected Profit Sunshine Biopharma|SBFM - P/E Multiple|Market Cap to Projected Earnings Sunshine Biopharma Inc.|SBFM - Price/Earnings to Growth Ratio|Company Value to EBITDA Sunshine Biopharma|SBFM - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Sunshine Biopharma|SBFM - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months sunshinebiopharma.com|SBFM - Earnings growth in current year|Earnings growth forecast for next year Sunshine Biopharma
- total revenue and sales volume data:
Fundamental company analysis:Sunshine Biopharma Inc. (SBFM)
The combination of oncology drug development and generic sales allows Sunshine Biopharma (SBFM) to balance innovation with stable cash flow. An analysis of the company's P/S chart demonstrates the ratio of market capitalization to annual revenue, which helps investors determine the degree of business overvaluation and promptly identify any gap between the issuer's fundamental earnings and its current exchange value.
Competing companies
Price-to-Revenue Coefficient beigene.com|Halozyme - Market Cap to Revenue|P/S Multiple Revolution Medicines Inc RVMD|AAPG - Price-to-Revenue Ratio|CGON (CG Oncology Therapeutics) - Market Cap to Revenue Ratio|UroGen Pharma Ltd. (URGN) - Price-to-Revenue Ratio|BCAX - Price-to-Revenue Coefficient|PSNL (Personalis) - P/S Multiple|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|Price-to-Revenue Coefficient Y-mAbs Corp|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|CADL: Market Cap to Revenue Ratio|Accuray - P/S Multiple|Price to Sales SELLAS Life Sciences|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Citius Oncology Inc - Market Capitalization-to-Revenue Ratio|HURA (TuHURA Biosciences Inc.) - P/S Multiple|Price-to-Revenue Ratio TARA|P/S Multiple FATE|Price-to-Revenue Coefficient aadibio.com|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Price to Sales|XBIT - Price-to-Revenue Ratio|Price-to-Sales Ratio CVM|OSTX: P/S Multiple|radiopharmtheranostics.com - Market Capitalization-to-Revenue Ratio|ARTV (Artiva Biotherapeutics Inc.) - P/S Multiple|P/S Multiple Adlai Nortye Limited|Price-to-Revenue Ratio Veru Inc. (VERU)|TPST (tempesttx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Xilio Therapeutics XLO|RENB - Market Cap to Revenue|Mural Bio - P/S Multiple|KAPA - P/S Multiple|onkuretherapeutics.com (OKUR) - Price-to-Revenue Ratio|GDTC - Price-to-Revenue Coefficient|CRIS (Curis Inc.) - P/S Multiple|Price-to-Revenue Ratio APLM|P/S Multiple THAR|ADVB: Price-to-Sales Ratio|Price-to-Revenue Ratio Genprex, Inc. GNPX|CLDI - Market Cap to Revenue|Xenetic Bio - P/S Multiple|Salarius Pharmaceuticals Inc (SLRX) - Market Cap to Revenue|PPBT: P/S Multiple|American Oncology Network, Inc. (AONC) - P/S Multiple|Price-to-Revenue Ratio BeiGene, Ltd.|Market Cap to Revenue Ratio CKPT (checkpointtx.com)|P/S Multiple ELEV|Market Cap to Revenue icadmed.com ICAD|P/S Multiple IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Price to Sales|VIRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Market Cap to Revenue|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio
